Moderna, Inc. has inched ahead of arch-rivals Pfizer Inc. and BioNTech SE in the race to get a combined COVID-19 and flu vaccine approved. Phase III data on mRNA-1083 suggests that the combo jab works better than marketed single-virus shots, and Moderna reckons it can get the product to market in time for next year’s flu season.
Moderna Pips Pfizer/BioNTech In Combo Jab Race
The company reported a late-stage success with its COVID-19 and flu combo vaccine, and says it can hit the market next year.
